Sfoglia per RIVISTA
JOURNAL OF CLINICAL ONCOLOGY
Collezione ASL Torino 4

  

Items : 8

Health-related quality of life (QoL) in randomized phase III trials in oncology: Association between results of QoL, results of primary endpoint and drug approval in Journal of Clinical Oncology

2024
ASL Torino 4

Paratore C; Schiavone R; Zichi C; Caglio A; Gamba T; Bombaci S; Vellani G; Marandino L; Perrone F; Di Maio M;

First line avelumab in PD-L1+ve metastatic or locally advanced urothelial cancer (aUC) patients unfit for cisplatin (cis): The ARIES trial in Journal of Clinical Oncology

2022
ASL Torino 4

Sperduti I; Fornarini G; Masini C; Aprile G; Milesi L; Spina F; Rizzo M; Verri E; Ermacora P; Milella M; Buti S; Santini D; Naglieri E; Galli L; Battelli N; Buttigliero C; Caserta C; Ciccarese C; Brunelli M; Iacovelli R;

First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study in Journal of Clinical Oncology

2022
ASL Torino 4

Berruti A; Fassnacht M; Libè R; Lacroix A; Kastelan D; Haak H; Arlt W; Decoudier B; Lasolle H; Bancos I; Quinkler M; Barisson Villares Fragoso MC; Canu L; Puglisi S; Bourdeau I; Baudin E; Berchialla P; Beuschlein F; Bertherat J; Terzolo M;

SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebocontrolled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC) in Journal of Clinical Oncology

2022
ASL Torino 4

Rudin CM; Liu SV; Lu S; Soo RA; Hong MH; Lee J-S; Bryl M; Dumoulin DW; Rittmeyer A; Chiu C-H; Ozyilkan O; Navarro A; Novello S; Ozawa Y; Meng R; Hoang T; Lee A; Wen X; Huang M; Reck M;

TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)-Exploration of germline DDR alteration landscape and potential associations with antitumor activity in Journal of Clinical Oncology

2022
ASL Torino 4

Dorff TB; Fizazi K; Laird D; Barthélémy P; Delva R; Maruzzo M; Stirling A; MacHiels J-PH; Dumez H; Renard V; Hopkins J; Albacker LA; Chen H-C; Healy CG; Chelliserry J; Van Oort IM; Scagliotti GV; De Bono JS; Mehra N;

Patient self-evaluation of side-effects related to adjuvant chemotherapy in breast cancer: A prospective study in Journal of Clinical Oncology

2015
ASL Torino 4
ASL Asti
AOU San Luigi di Orbassano
ASL VCO

Montemurro F; Mittica G; Cagnazzo C; Foresto M; Longo V; Berchialla P; Solinas G; Culotta P; Martinello R; Calori A; Grasso B; Volpone C; Bertola G; Parola G; Del Torre M; Giuliano PL; Aglietta M; Ballari A;

Modeling acute urinary toxicity after radiotherapy for prostate cancer in Journal of Clinical Oncology

2014
ASL Torino 4

Carillo V; Rancati T; Cozzarini C; Villa S; Botti A; Borca VC; Cattari G; Civardi F; Esposti CD; Franco P; Girelli G; Maggio A; Muraglia A; Palombarini M; Pierelli A; Pignoli E; Vavassori V; Zeverino M; Valdagni R; Fiorino C;

Imatinib mesylate (IM) therapy in elderly patients affected by advanced gastrointestinal stromal tumor (GIST) in Journal of Clinical Oncology

2011
ASL Torino 4

D'Ambrosio L; Ponzetti A; Lista P; Bombaci S; Palesandro E; Galizia D; Aliberti S; Allione P; Manca A; Gallo S; Grignani G; Aglietta M;